Probiotic as a therapeutic tool in the skin-lung-bowel axis

• Grant number: 19/12324-1
• Support Opportunities: Regular Research Grants
• Duration: May 01, 2020 - April 30, 2022
• Field of knowledge: Biological Sciences - Physiology - Physiology of Organs and Systems
• Principal Investigator: Caroline Marcantonio Ferreira
• Grantee: Caroline Marcantonio Ferreira
• Host Institution: Instituto de Ciências Ambientais, Químicas e Farmacêuticas (ICAQF). Universidade Federal de São Paulo (UNIFESP). Campus Diadema. Diadema , SP, Brazil
• Associated researchers: Marco Aurélio Ramirez Vinolo

Abstract

The incidence and prevalence of chronic inflammatory diseases like asthma and inflammatory bowel disease (IBD) are rising worldwide, affecting primarily countries with Western lifestyles. Epidemiological data show that there is an important relationship between allergic skin diseases and asthma. Asthma has also been associated to IBD development. Skin, lung and gut are barrier tissues. That protect the organism against pathogens. The mechanisms by which these diseases are related is unclear. It is known that gut microbiota and its metabolic products, such as short chain fatty acids (SCFAs) are involved in the development of dermatitis, asthma and IBD but it is not known whether it is responsible for the link between these diseases. Preliminary data suggest that dermatitis leads to changes in the pulmonary and intestinal homeostasis. In this study, our goal is to understand if probiotic strategies may prevent dermatitis from leading to changes in pulmonary and intestinal homeostasis. Firstly, we will evaluate in experimental model the consequences of dermatitis for pulmonary and gut homeostasis, as well as the role of the gut microbiota through the use of germ-free animals. Next, we will evaluate if the treatment with probiotic is able to inhibit the pulmonary and intestinal affection caused by dermatitis. Although immunological regulation by microbiota has been thoroughly studied in isolated parts of the mucosa, studies on the integration of lung and gut mucosa is scant. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

RIBEIRO, W. R.; QUEIROZ, A. G.; MENDES, E.; CASARO, M. B.; NASCIMENTO, C. M.; COELHO, L. S. S. F.; MARTINS, F. S.; LEITE-SILVA, V. R.; FERREIRA, C. M.. Preventive oral supplementation with Bifidobacterium longum 5(1A) alleviates oxazolone-induced allergic contact dermatitis-like skin inflammation in mice. BENEFICIAL MICROBES, v. 12, n. 2, p. 199-209, 2021. (12/50410-8, 19/12324-1)

CASARO, MATEUS B.; THOMAS, ANDREW M.; MENDES, EDUARDO; FUKUMORI, CLAUDIO; RIBEIRO, WILLIAN R.; OLIVEIRA, FERNANDO A.; CRISMA, AMANDA R.; MURATA, GILSON M.; BIZZARRO, BRUNA; SA-NUNES, ANDERSON; et al. A probiotic has differential effects on allergic airway inflammation in A/J and C57BL/6 mice and is correlated with the gut microbiome. MICROBIOME, v. 9, n. 1, JUN 10 2021. (12/50410-8, 16/13496-2, 19/12324-1)

NASCIMENTO, CAROLINA MARTINS; CASARO, MATEUS CAMPOS; PEREZ, EVELYN ROXANA; RIBEIRO, WILLIAN RODRIGUES; MAYER, MARCIA PINTO ALVES; ISHIKAWA, KARIN HITOMI; LINO-DOS-SANTOS-FRANCO, ADRIANA; PEREIRA, JOICE NAIARA BERTAGLIA; FERREIRA, CAROLINE MARCANTONIO. Experimental allergic airway inflammation impacts gut homeostasis in mice. HELIYON, v. 9, n. 6, p. 11-pg., 2023-06-01. (19/12324-1, 21/06751-4)